Two crystal forms of GL-V9 and preparation method thereof

By determining and preparing new GL-V9 crystal forms, the bioavailability problems caused by crystal form differences in the prior art are solved, higher bioavailability and stability are achieved, and drug efficacy and storage conditions are met, providing more Good market value and industrial production potential.

CN118894832AActive Publication Date: 2024-11-05CHINA PHARM UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410965694.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-05
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Different crystal forms of GL-V9 in the prior art lead to differences in drug solubility and bioavailability, affecting the efficacy and production equivalence of drugs, and the reported bioavailability of crystal forms needs to be optimized.

Method used

Two new GL-V9 crystal forms and their preparation methods are provided. The crystal forms characteristics are determined by X-ray powder diffraction spectra detected by Cu-Kα radiation, and the slow dropping addition method is prepared under different solvent combinations and heating conditions to prepare stable Crystal form with high qualities, no moisture induction, and solubility meets the requirements.

Benefits of technology

It achieves higher bioavailability and stability, avoids drug transformation, meets drug efficacy and storage conditions requirements, and provides better market value and industrial production potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894832A_ABST
    Figure CN118894832A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemistry, and particularly relates to two crystal forms of GL-V9 and a preparation method thereof. The two crystal forms of the GL-V9 are respectively a crystal form II and a crystal form III; the two GL-V9 crystal forms are good in stability, solubility and hygroscopicity meet medicinal requirements, and the preparation method is simple and low in cost and has important value for research, development and production of the medicine. And compared with the crystal form in the prior art, the bioavailability is higher.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to two GL-V9 crystal forms and preparation methods thereof. Background Art

[0002] GL-V9 is a derivative of the flavonoid compound wogonin, with a molecular formula of C24H27NO5 and a chemical name of 5-hydroxy-7-(4-pyrrol-1-yl)butoxy-8-methoxyflavone. Its structural formula is shown in formula (I).

[0003]

[0004] Studies have shown that GL-V9 has a wide range of pharmacological activities. Currently, the clinical research approval (IND) has been submitted in April 2024. It is expected to become a new type of leukemia treatment drug, providing new options for clinical treatment.

[0005] Different crystal forms of the same drug often lead to differences in drug solubility, thereby affecting the dissolution and bioavailability of the drug, which in turn affects the absorption and utilization of the drug in the body, resulting in different drug efficacy. Therefore, the crystal form is one of the primary issues that must be paid attention to when selecting the dosage form in drug development, and it is also one of the key factors in whether the drug can be effectively absorbed. In addition, by studying the crystal form characteristics of the drug, the formulation process can be optimized, the performance of solid drug preparations can be improved, and the equivalence of different batches of drugs in the production process can be effectively guaranteed. Therefore, screening for the right crystal form is crucial for subsequent drug development.

[0006] A Chinese invention patent with application publication number CN115785048A discloses a GL-V9 crystal form and a preparation method thereof. It reports that the crystal form I of GL-V9 has relatively stable properties, but its bioavailability needs to be optimized. Summary of the invention

[0007] The purpose of the present invention is to solve the deficiencies in the prior art and provide two crystal forms of GL-V9 and a preparation method thereof.

[0008] The crystal form of the present invention has good stability, purity, and non-hygroscopicity, and its solubility and hygroscopicity meet the requirements for pharmaceutical use. The preparation method is simple and low-cost, and it is suitable for large-scale industrial production, which is of great value for the research and development and production of the drug. The invention also invented a preparation method for two new crystal solid substances of GL-V9. The invention involves using two new crystal solid substances to determine the bioavailability, which is higher than the bioavailability of previously reported crystal forms.

[0009] In order to achieve the above object, the present invention is achieved through the following technical solutions:

[0010] In the first aspect, the present invention provides a GL-V9 crystal form, which is crystal form II. In the X-ray powder diffraction spectrum detected by Cu-Kα radiation, 2 θ There are diffraction peaks at: 5.023°, 5.220°, 8.058°, 8.284°, 10.016°, 12.056°, 13.169°, 15.084°, 16.354°, 16.574°, 20.186°, 25.463°, 2 θ The value accuracy is ±0.2°.

[0011] When Form II is heated to 143.8°C, an endothermic peak begins to appear. There is no weight loss before the endothermic peak appears, indicating that it is an anhydrous form and a non-solvate.

[0012] In addition, a preparation method thereof is provided, and the method is as follows:

[0013] Heat GL-V9 and dissolve it in solvent a; under heating, slowly drop solvent b, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form II; wherein solvent a is selected from one or a mixture of two or more of 95% ethanol, DMSO, DMF, NMP or DMA, and solvent b is selected from one or a mixture of two or more of water, isopropyl ether or methyl tert-butyl ether;

[0014] or,

[0015] Heat GL-V9 and dissolve it in solvent c, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form II; wherein the solvent c is selected from one or a mixture of two or more of 95% ethanol, DMSO, DMF, NMP or DMA.

[0016] Preferably, the volume ratio of solvent a to solvent b is 1:1-10, the mass volume ratio of GL-V9 to solvent a is 5:100-300, unit, g / mL; the heating temperature is 35-100°C, the crystallization temperature is -20-60°C, and the crystallization time is 1-5 hours.

[0017] Preferably, the mass volume ratio of GL-V9 to solvent c is 5:100-300, unit, g / mL; the heating temperature is 35-100°C, the crystallization temperature is -20-60°C, and the crystallization time is 1-5 hours.

[0018] In a second aspect, the present invention provides another GL-V9 crystal form, which is crystal form III. In the X-ray powder diffraction spectrum detected by Cu-Kα radiation, 2 θThe diffraction peaks are at 5.087°, 6.557°, 8.033°, 8.370°, 10.069°, 11.807°, 12.136°, 13.026°, 13.825°, 15.078°, 16.216°, 16.656°, and 20.126°. θ The value accuracy is ±0.2°.

[0019] When Form III is heated to 143.2°C, an endothermic peak begins to appear. There is no weight loss before the endothermic peak appears, indicating that it is an anhydrous form and a non-solvate.

[0020] In addition, a preparation method thereof is provided, and the method is as follows:

[0021] Heat GL-V9 and dissolve it in solvent d; under heating, slowly drop solvent e, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form III; wherein the solvent d is selected from one or a mixture of two or more of tetrahydrofuran, dioxane, n-butanol or ethyl acetate, and the solvent e is selected from one or a mixture of two or more of water, isopropyl ether or methyl tert-butyl ether;

[0022] or,

[0023] Heat GL-V9 and dissolve it in solvent f, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form III; wherein the solvent f is selected from tetrahydrofuran, dioxane, n-butanol or ethyl acetate, a mixture of two or more thereof.

[0024] Preferably, the volume ratio of solvent d to solvent e is 1:1-10, the mass volume ratio of GL-V9 to solvent d is 5:100-300, unit, g / mL; the heating temperature is 35-100°C, the crystallization temperature is -20-60°C, and the crystallization stirring time is 1-5 hours.

[0025] Preferably, the mass volume ratio of GL-V9 to solvent f is 5:100-300, unit, g / mL; the heating temperature is 35-100°C, the crystallization temperature is -20-60°C, and the crystallization stirring time is 1-5 hours.

[0026] The present invention has the following beneficial effects: (1) The present invention is different from the prior art in that a new crystalline solid substance of GL-V9 is discovered. Based on the existence state of the solid substance of GL-V9 and combined with the crystal screening technology, the existence types and state characteristics of different crystal forms of GL-V9 are developed at the raw material level of the active ingredient of the drug, and the crystal form research is combined with the pharmacodynamics research to provide a basis for the development of a crystalline solid drug of GL-V9 with the best clinical efficacy.

[0027] (2) The crystal form provided by the present invention has good stability and can well avoid crystal transformation during drug storage and development, thereby avoiding changes in bioavailability and efficacy. The crystal form provided by the present invention is almost non-hygroscopic, meets the requirements of bioavailability and efficacy, is not demanding on storage conditions, and is convenient for long-term storage. Compared with the reported crystal form I, it has better bioavailability and high market value. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 : Powder X-ray diffraction pattern of the solid sample of Form II of GL-V9;

[0029] Figure 2 : DSC spectrum of the solid sample of Form II of GL-V9;

[0030] Figure 3 : TGA spectrum of the solid sample of Form II of GL-V9;

[0031] Figure 4 : Powder X-ray diffraction pattern of the solid sample of Form III of GL-V9;

[0032] Figure 5 : DSC spectrum of the solid sample of Form III of GL-V9;

[0033] Figure 6 : TGA spectrum of the solid sample of Form III of GL-V9;

[0034] Figure 7 : X-ray diffraction superposition diagrams of GL-V9 crystal form II stored under different conditions;

[0035] Figure 8 : HPLC overlay of Form II of GL-V9 stored under different conditions;

[0036] Fig. 9 : X-ray diffraction overlays of GL-V9 crystal form III stored under different conditions;

[0037] Fig.10 : HPLC overlay of Form III of GL-V9 stored under different conditions. DETAILED DESCRIPTION

[0038] The technical scheme of the present invention is further illustrated by specific examples below, but the protection scope of the present invention is not limited thereto. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified.

[0039] The analysis and detection conditions of the present invention are as follows:

[0040] The X-ray powder diffraction pattern of the present invention was collected on a D8 ADVANCE X-ray powder diffractometer. The method parameters of the X-ray powder diffraction of the present invention are as follows:

[0041] X-ray reflection parameters: Cu, K-α radiation

[0042] Kα11.5406; Kα21.54443

[0043] Kα2 / Kα1 intensity ratio: 0.50

[0044] Voltage: 40 kilovolts (kV)

[0045] Current: 40 milliamperes (mA)

[0046] Scanning range: from 3.0 to 40.0 degrees

[0047] Step size: 0.02°.

[0048] The differential scanning calorimetry (DSC) diagram of the present invention was collected on a NETZSCH DSC 204. The method parameters of the differential scanning calorimetry (DSC) of the present invention are as follows:

[0049] Heating rate: 10℃ / min

[0050] Scanning range: 40.0~350.0℃

[0051] Protective gas: nitrogen.

[0052] The thermogravimetric analysis (TGA) graph of the present invention was collected on NETZSCH TG209. The method parameters of the thermogravimetric analysis (TGA) of the present invention are as follows:

[0053] Heating rate: 10℃ / min

[0054] Scanning range: 25.0~350.0℃

[0055] Protective gas: nitrogen.

[0056] Example 1

[0057] The preparation method of GL-V9 crystal form II comprises the following steps:

[0058] Add 5 g of GL-V9 into 150 mL of DMF, heat to 60°C, heat and stir until completely dissolved and clarified, then keep warm for half an hour, slowly cool to 10°C and stir for 5 hours, filter, wash the filter cake with DMF, and dry to obtain GL-V9 crystal form II.

[0059] The GL-V9 crystal form II solid obtained in this example was subjected to X-ray powder diffraction analysis (eg Figure 1As shown), DSC analysis (as Figure 2 ) and TGA analysis (as shown Figure 3 shown).

[0060] The chemical purity and crystal purity of the GL-V9 crystal form II solid described in the present invention are both greater than 95%. When powder X-ray diffraction analysis is performed using CuKα radiation experimental conditions, the diffraction peak position 2-Theta value (dvalue) or peak area value (Intensity) or d value diffraction peak relative intensity peak height value (Intensity%) are shown in Table 1.

[0061] Table 1 Powder X-ray diffraction peak values ​​of GL-V9 crystal form II solid sample

[0062]

[0063] The solid substance of GL-V9 crystal form II has an endothermic peak in its DSC spectrum, and its transition value is 143.8℃ (such as Figure 2 GL-V9 crystal form II solid material, when heated to 143.8 ° C, has no weight loss (as shown in Figure 3 shown).

[0064] Example 2

[0065] The preparation method of GL-V9 crystal form II comprises the following steps:

[0066] Add 5 g of GL-V9 into 150 mL of DMF, heat to 60°C until completely dissolved and clarified, slowly add 200 mL of water dropwise while stirring, and after the addition, slowly cool to 20°C and stir for 5 hours, filter, wash the filter cake with water, and dry to obtain GL-V9 crystal form II.

[0067] Example 3

[0068] The preparation method of GL-V9 crystal form II comprises the following steps:

[0069] Add 5 g of GL-V9 into 150 mL of DMF, heat to 60°C until completely dissolved and clarified, slowly add 200 mL of isopropyl ether dropwise while stirring, and after the addition, slowly cool to 20°C and stir for 5 hours, filter, wash the filter cake with isopropyl ether, and dry to obtain GL-V9 Form II.

[0070] Example 4

[0071] The preparation method of GL-V9 crystal form III comprises the following steps:

[0072] Add 5 g of GL-V9 to 150 ml of tetrahydrofuran, heat to 60°C, heat and stir until completely dissolved and clarified, then keep warm for half an hour, slowly cool to 10°C and stir for 5 hours, filter, wash the filter cake with tetrahydrofuran, and dry to obtain GL-V9 crystal form III.

[0073] The GL-V9 crystal form III solid obtained in this example was subjected to X-ray powder diffraction analysis (eg Figure 4 As shown), DSC analysis (as Figure 5 ) and TGA analysis (as shown Figure 6 shown).

[0074] The chemical purity and crystal purity of the GL-V9 solid of the present invention are both greater than 95%. When powder X-ray diffraction analysis is performed using CuKα radiation experimental conditions, the diffraction peak position 2-Theta value (dvalue) or peak area value (Intensity) or d value diffraction peak relative intensity peak height value (Intensity%) are shown in Table 2.

[0075] Table 2 Powder X-ray diffraction peak values ​​of GL-V9 crystal form III solid sample

[0076]

[0077] The solid substance of GL-V9 crystal form III has an endothermic peak in its DSC spectrum, and its transition value is 143.2℃ (such as Figure 5 GL-V9 crystalline form III solid material, when heated to 143.2 ° C, has no weight loss (as shown in Figure 6 shown).

[0078] Example 5

[0079] The preparation method of GL-V9 crystal form III comprises the following steps:

[0080] Add 5 g of GL-V9 into 100 mL of tetrahydrofuran, heat to 60°C until completely dissolved and clarified, slowly add 200 mL of water dropwise while stirring, and after the addition, slowly cool to 20°C and stir for 5 hours, filter, wash the filter cake with water, and dry to obtain GL-V9 crystal form III.

[0081] Example 6

[0082] The preparation method of GL-V9 crystal form III comprises the following steps:

[0083] Add 5 g of GL-V9 to 150 mL of acetone, heat to 60°C until completely dissolved and clarified, slowly add 200 mL of isopropyl ether dropwise while stirring, and after the addition, slowly cool to 20°C and stir for 5 hours, filter, wash the filter cake with isopropyl ether, and dry to obtain GL-V9 Form III.

[0084] Experimental Example 1: Hygroscopicity test of GL-V9 crystal form II

[0085] Take a dry stoppered glass weighing bottle (outer diameter 50mm, height 15mm), place it in an artificial climate box (set temperature 25℃±1℃, relative humidity 80%±2%) one day before the test, and accurately weigh it (20.0105g). Take the GL-V9 crystal obtained in Example 1 and spread it in the above weighing bottle, with a thickness of about 1mm, and accurately weigh it (20.9979g). Open the weighing bottle and place it under the above constant temperature and humidity conditions with the bottle cap for 24 hours. Cover the weighing bottle lid and accurately weigh it (20.9997g).

[0086] Weight gain percentage = (20.9997g-20.9979g) / (20.9979g-20.0105g)×100%=0.18%

[0087] Definition of hygroscopic weight gain (Guidelines for hygroscopicity test of drugs in Appendix 9103 of the 2020 edition of the Chinese Pharmacopoeia, experimental conditions: 25℃±1℃, 80% relative humidity):

[0088] Deliquescent: Absorbs sufficient water to form a liquid.

[0089] Highly hygroscopic: weight gain due to moisture absorption is not less than 15%.

[0090] Hygroscopic: Weight gain due to moisture absorption is less than 15% but not less than 2%.

[0091] Slightly hygroscopic: weight gain due to moisture absorption is less than 2% but not less than 0.2%.

[0092] No or almost no hygroscopicity: weight gain due to moisture is less than 0.2%.

[0093] The results show that the crystal form II of Example 1 of the present invention increases in weight by 0.18% after equilibrium at a relative humidity of 80%, which is no or almost no hygroscopicity.

[0094] Experimental Example 2: Stability test of GL-V9 crystal form II

[0095] About 200 mg of the GL-V9 crystal sample prepared in Example 1 was placed in an open container at 25°C, 60% RH and 40°C, 75% RH, and the XRPD and HPLC purity of the crystal form II sample was measured after 30 days. The experimental results are shown in Table 3. The XRPD superposition diagrams of the crystal form II under different conditions are shown in Table 3. Figure 7 The HPLC superposition diagrams of Form II under different conditions are shown in Figure 8 shown.

[0096] Table 3 Stability of GL-V9 Form II

[0097]

[0098]

[0099] The results show that after 30 days of storage at 25°C, 60% RH and 40°C, 75% RH, the sample crystal form is stable and the purity is almost unchanged. The XRPD spectrum is superimposed as shown in Figure 7, and the HPLC superimposed as shown in Figure 8. It can be seen that the spectra before and after storage are highly consistent.

[0100] Experimental Example 3: Bioavailability Test of GL-V9 Form II

[0101] Three male SD rats and three female SD rats were provided by Qinglongshan Animal Breeding Farm in Jiangning District, Nanjing, license number: SCXK (Su) 2022-0011. The weight range is 180g to 220g. After purchase, they were raised in the laboratory of the Experimental Animal Center for 3 days before use. They were fasted for 12 hours before administration and had free access to water during the experiment. Oral administration was 50 mg / kg by gavage, and intravenous administration was 5 mg / kg by tail vein.

[0102] Preparation of dosing solution:

[0103] The solution for intragastric administration was prepared with 0.5% CMC-Na and mixed evenly before administration; the solution for intravenous administration was prepared with 0.3M hydroxypropyl-β-cyclodextrin / lactic acid (99 / 1, v / v).

[0104] Before and 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after oral administration, about 200 μl of blood was collected and placed in an EP tube containing 1% sodium heparin. The blood was centrifuged at 8000 rpm for 5 minutes to separate the plasma, determine the plasma drug concentration, and calculate the pharmacokinetic parameters.

[0105] For intravenous administration, approximately 100 μl of blood was collected into EP tubes containing 1% sodium heparin before and 2 min, 15 min, 45 min, 2 h, 4 h, 8 h, 12 h, and 24 h after administration. The blood was centrifuged at 8000 rpm for 5 min to separate the plasma, determine the plasma drug concentration, and calculate the pharmacokinetic parameters (PK parameters were calculated using WinNonlin version 6.4).

[0106] The results are shown in Table 4:

[0107] Table 4 Bioavailability data of GL-V9 crystal form II in SD rats

[0108]

[0109] The results showed that the oral bioavailability of GL-V9 Form II was high, at 11.00%, which was higher than that of Form I reported in patent CN115785048A.

[0110] Experimental Example 4: Hygroscopicity test of GL-V9 crystal form III

[0111] Take a dry stoppered glass weighing bottle (outer diameter 50mm, height 15mm), place it in an artificial climate box (set temperature 25℃±1℃, relative humidity 80%±2%) one day before the test, and accurately weigh it (20.0102g). Take the GL-V9 crystal obtained in Example 4 and spread it in the above weighing bottle, with a thickness of about 1mm, and accurately weigh it (20.9981g). Open the weighing bottle and place it under the above constant temperature and humidity conditions with the bottle cap for 24 hours. Cover the weighing bottle lid and accurately weigh it (20.9996g).

[0112] Weight gain percentage = (20.9996g-20.9981g) / (20.9981g-20.0102g)×100%=0.15%

[0113] Definition of hygroscopic weight gain (Guidelines for hygroscopicity test of drugs in Appendix 9103 of the 2020 edition of the Chinese Pharmacopoeia, experimental conditions: 25℃±1℃, 80% relative humidity):

[0114] Deliquescent: Absorbs sufficient water to form a liquid.

[0115] Highly hygroscopic: weight gain due to moisture absorption is not less than 15%.

[0116] Hygroscopic: Weight gain due to moisture absorption is less than 15% but not less than 2%.

[0117] Slightly hygroscopic: weight gain due to moisture absorption is less than 2% but not less than 0.2%.

[0118] No or almost no hygroscopicity: weight gain due to moisture is less than 0.2%.

[0119] The results show that the crystal form III of Example 4 of the present invention increases in weight by 0.15% after equilibrium at a relative humidity of 80%, which is no or almost no hygroscopicity.

[0120] Experimental Example 5: Stability test of GL-V9 crystal form III

[0121] About 200 mg of the GL-V9 crystal sample prepared in Example 4 was placed in an open state at 25°C, 60% RH and 40°C, 75% RH, and the XRPD and HPLC purity of the crystal form III sample was measured after 30 days. The experimental results are shown in Table 5. The XRPD superposition diagrams of the crystal form III under different conditions are shown in Table 5. Fig. 9 The HPLC superposition diagrams of Form III under different conditions are shown in Fig.10 shown.

[0122] Table 5 Stability of GL-V9 Form III

[0123]

[0124] The results show that after 30 days of storage at 25°C, 60% RH and 40°C, 75% RH, the crystal form of GL-V9 Form III is stable and the purity remains almost unchanged. Fig. 9 As shown, the HPLC overlay is as follows Fig.10 As shown, it can be seen that the spectra before and after placement are highly consistent.

[0125] Experimental Example 6: Bioavailability Test of GL-V9 Form III

[0126] Three male SD rats and three female SD rats were provided by Qinglongshan Animal Breeding Farm in Jiangning District, Nanjing, license number: SCXK (Su) 2022-0011. The weight range is 180g to 220g. After purchase, they were raised in the laboratory of the Experimental Animal Center for 3 days before use. They were fasted for 12 hours before administration and had free access to water during the experiment. Oral administration was 50 mg / kg by gavage, and intravenous administration was 5 mg / kg by tail vein.

[0127] Preparation of dosing solution:

[0128] The solution for intragastric administration was prepared with 0.5% CMC-Na and mixed evenly before administration; the solution for intravenous administration was prepared with 0.3M hydroxypropyl-β-cyclodextrin / lactic acid (99 / 1, v / v).

[0129] Before and 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after oral administration, about 200 μl of blood was collected and placed in an EP tube containing 1% sodium heparin. The blood was centrifuged at 8000 rpm for 5 minutes to separate the plasma, determine the plasma drug concentration, and calculate the pharmacokinetic parameters.

[0130] For intravenous administration, approximately 100 μl of blood was collected into EP tubes containing 1% sodium heparin before and 2 min, 15 min, 45 min, 2 h, 4 h, 8 h, 12 h, and 24 h after administration. The blood was centrifuged at 8000 rpm for 5 min to separate the plasma, determine the plasma drug concentration, and calculate the pharmacokinetic parameters (PK parameters were calculated using WinNonlin version 6.4).

[0131] The results are shown in Table 6:

[0132] Table 6 Bioavailability data of GL-V9 crystal form III in SD rats

[0133]

[0134] The results showed that the oral bioavailability of GL-V9 Form III was high, at 12.06%, which was higher than that of Form I reported in patent CN115785048A.

[0135] The above shows and describes the basic principles, main features and advantages of the present invention. However, the above is only a specific embodiment of the present invention, and the technical features of the present invention are not limited thereto. Any other implementation methods derived by any technician in the field without departing from the technical solution of the present invention should be included in the patent scope of the present invention.

Claims

1. A GL-V9 crystal form, which is crystal form II, has an X-ray powder diffraction spectrum detected by Cu-Kα radiation. θ There are diffraction peaks at: 5.023°, 5.220°, 8.058°, 8.284°, 10.016°, 12.056°, 13.169°, 15.084°, 16.354°, 16.574°, 20.186°, 25.463°, 2 θ The value accuracy is ±0.2°.

2. The GL-V9 crystal form according to claim 1, characterized in that: When Form II is heated to 143.8°C, an endothermic peak begins to appear. There is no weight loss before the endothermic peak appears, indicating that it is an anhydrous form and a non-solvate.

3. The method for preparing the GL-V9 crystal form according to claim 1 or 2, characterized in that: The method is as follows: Heat GL-V9 and dissolve it in solvent a; under heating, slowly drop solvent b, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form II; wherein solvent a is selected from one or a mixture of two or more of 95% ethanol, DMSO, DMF, NMP or DMA, and solvent b is selected from one or a mixture of two or more of water, isopropyl ether or methyl tert-butyl ether; or, Heat GL-V9 and dissolve it in solvent c, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form II; wherein the solvent c is selected from one or a mixture of two or more of 95% ethanol, DMSO, DMF, NMP or DMA.

4. The method for preparing the GL-V9 crystal form according to claim 3, characterized in that: The volume ratio of solvent a to solvent b is 1:1-10, and the mass volume ratio of GL-V9 to solvent a is 5:100-300, unit, g / mL; the heating temperature is 35-100° C., the crystallization temperature is -20-60° C., and the crystallization time is 1-5 hours.

5. The preparation method according to claim 3, characterized in that: The mass volume ratio of GL-V9 to solvent c is 5:100-300, unit, g / mL; the heating temperature is 35-100° C., the crystallization temperature is -20-60° C., and the crystallization time is 1-5 hours.

6. A GL-V9 crystal form, which is crystal form III, has an X-ray powder diffraction spectrum detected by Cu-Kα radiation, 2 θ The diffraction peaks are at 5.087°, 6.557°, 8.033°, 8.370°, 10.069°, 11.807°, 12.136°, 13.026°, 13.825°, 15.078°, 16.216°, 16.656°, and 20.126°. θ The value accuracy is ±0.2°.

7. The GL-V9 crystal form according to claim 6, characterized in that: When Form III is heated to 143.2°C, an endothermic peak begins to appear. There is no weight loss before the endothermic peak appears, indicating that it is an anhydrous form and a non-solvate.

8. The method for preparing the GL-V9 crystal form according to claim 6 or 7, characterized in that: The method is as follows: Heat GL-V9 and dissolve it in solvent d; under heating, slowly drop solvent e, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form III; wherein the solvent d is selected from one or a mixture of two or more of tetrahydrofuran, dioxane, n-butanol or ethyl acetate, and the solvent e is selected from one or a mixture of two or more of water, isopropyl ether or methyl tert-butyl ether; or, Heat GL-V9 and dissolve it in solvent f, keep warm and stir; slowly cool down to precipitate solid, filter and dry to obtain GL-V9 crystal form III; wherein the solvent f is selected from tetrahydrofuran, dioxane, n-butanol or ethyl acetate, a mixture of two or more thereof.

9. The method for preparing the GL-V9 crystal form according to claim 8, characterized in that: The volume ratio of solvent d to solvent e is 1:1-10, the mass volume ratio of GL-V9 to solvent d is 5:100-300, unit, g / mL; the heating temperature is 35-100° C., the crystallization temperature is -20-60° C., and the crystallization stirring time is 1-5 hours.

10. The method for preparing the GL-V9 crystal form according to claim 8, characterized in that: The mass volume ratio of GL-V9 to solvent f is 5:100-300, unit, g / mL; the heating temperature is 35-100° C., the crystallization temperature is -20-60° C., and the crystallization stirring time is 1-5 hours.

Citation Information

Patent Citations

  • Crystal form of linagliptin and preparation method thereof

    CN109748919A

  • Crystal form of prostacyclin derivative

    CN115611838A

  • GL-V9 crystal form and preparation method thereof

    CN115785048A

  • Preparation method of flavonoid compound GL-V9

    CN116655576A

  • Process for the preparation of rifaximin crystalline form

    WO2018178777A1